There was such a build up earlier in the year on news that was supposed to come out this June for ASCO. So much for that. The interview last week may explain why there wasn't that much interest in the vaccine. If they want to go it alone Fletcher is going to have to come up with $100 million. Does he have anything left to sell?
Don't bother listening to me. Listen to the audio of that Press Conference. Fletcher, Joseph Moscato, the Chairman John Barratt and the COO David Brusegard were all there saying that they were ringing in a new era and that the roll out was the big plan. All out of their own mouths. What happened to the stock? It went straight B-line down after this. The charts from the past 3 years show this.
Shreya is a private company. I don't think they need to say anything. Generex is obligated to its shareholders. If it is true that there was yet another long list of questions from the DCGI office then maybe Shreya threw in the towel? The fact that someone posted that there is financing until 2015 does not make one difference in this case. Fletcher is using it for his salary anyway.
I think Fletcher and his little staff might be the only dreamers left. After Labor Day what story are we going to hear next? If I had to wager I would bet that because they have no interested party for Antigen that Fletcher now put AE37 on the back burner. He is probably going to talk about Orallyn and try to raise some money to do some studies? We shall see how the show unfolds. But one thing is for sure. Fletcher and the Board of Directors continue to collect their salaries and do nothing for it.
There are examples of stocks that keep on trading until they get halted.
Fletcher's desperate move to make sure that the share price does not go under 2 cents. But let's face it where is the money to do any development or clinical studies on this? Really? Just an attempt to keep the salary going. No substance. No ability.
Yup, what a Master of Destruction. He won't ever step down because he wants to keep on collecting a salary to do nothing all day long year after year. He won't go out and find a partner and in fact he really can't go out and find a partner after his distribution. Who the hell would risk their own business on this?
I don't know about this theory. If you were there at the Press Conference in New York right after Fletcher took the reigns it looked to me like a whole new agenda was going to take place. Roll out of Antigen Express. The problem became pretty clear that they had no clue as to how a roll out was to be done. If this is not the case the temporary replacement Mark Fletcher would have stepped down once he realized he was in over his head. At 2 cents a share we will never know the whole truth. But I think personal agendas won and the rest of us paid for it.
The storm already hit the company. Everything is wiped out to the ground. No more assets, no more Oral-lyn and without $100 million for Phase III no more AE37 development.
Well the convertible debenture holders got sucked in to put up more money thinking that something was going to happen at ASCO. Pretty sure they are looking for another biotech company to invest in. This one has no life left.
No one wants to dirty their hands with this company. All of their actions up until now are not those of real business people and that is why serious investors or partners stay the heck away. Quite frankly who cares what conferences Dr. Anderson attends? The company for all intensive purposes is not in the diabetes business any longer. Are we to take this seriously? Please.
I don't know man. Did you hear about the new rules at the SEC? Convertible debentures are no longer acceptable. Since that is the only type of financing Fletcher was able to get up until now where is any new financing going to come from?
Not dead money for those collecting salaries and fees (ahem Fletcher, David Brusegard, Board of Directors etc. etc.)
Boy is that the truth. Fletcher should have been gone well over a year ago. No roll out of Antigen = no more salary or position for Fletcher. No action on their part has shareholders wondering alright.
They are just trying to jack the price up again. Dejavu. Last year didn't they try to bump it up to about 4 cents and do another financing. Still did nothing with the money they raised except collect salaries and fees.
Did you read the quote in today's Press Release? Fletcher is pleased with the reception that Antigen Express received at ASCO? Really? Then why didn't they sign someone up at ASCO? They still need to shop it? Are they going to announce this one twice as well? Please.
The debenture holders finally giving up and jumping ship to another deal?
No company is going to dirty their hands with Fletcher and company. As long as he collects his salary he will keep the puppet show alive. Too bad the show stinks!
Buy out? I don't think anyone wants to get their hands dirty anymore with this destroyed company. I don't even think they could get anyone interested in being bought out by them. Who would tie up their company or technology with a CEO like Fletcher whose track record is sheer destruction.
Yeah sure. I don't buy that if the 2 1/2 employees are still around and following Fletcher's tail they are no different than he is. Money for nothing is their company song.